In collaborations with 14 cancer centers throughout the country, IBM will apply Watson Genomic Analytics, a cloud-based service, to implement evidence-based treatment decisions in oncology.
IBM announced this week that it has partnered with 14 major cancer centers in the United States to use Watson for the analysis of patient-specific genetic data to guide therapy.
Use of Watson in healthcare was one of the earliest applications envisioned after its famous "Jeopardy!" victory. And the pace of news about Watson in medicine has definitely picked up. @Point of Care, which made the list of our Best New Apps of 2014, uses Watson to help answer patient questions about multiple sclerosis. And Pathway Genomics plans to deliver personalized health advice based on a patient's genetic profile using Watson.
In a demonstration of its commitment, IBM recently launched a 2000-person Watson Health unit that will focus entirely on applications in medicine. At the same time, the company also announced a collaboration with Apple that will brings Watson's analytic power together with the piles of data being collected through HealthKit.
Complete report on Medpage Today: http://bit.ly/1JBPELW
Dr Kathryn Lindley Explains the Importance of Cardio-Obstetrics in Fellowship Programs
December 5th 2023Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, talks about why it’s important to incorporate cardio-obstetrics training into cardiovascular disease fellowship programs.
Read More
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
Trastuzumab Biosimilar Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers
December 5th 2023EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union (EU) for the treatment of patients with HER2-positive (HER2+) breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the European Union.
Read More